Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

doi:10.1016/j.eururo.2024.09.017

. 2025 Feb;87(2):157-216.

doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11.

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen¹, Fabio Turco², Ian D Davis³, Jason A Efstathiou⁴, Karim Fizazi⁵, Nicholas D James⁶, Neal Shore⁷, Eric Small⁸, Matthew Smith⁹, Christopher J Sweeney¹⁰, Bertrand Tombal¹¹, Thomas Zilli¹², Neeraj Agarwal¹³, Emmanuel S Antonarakis¹⁴, Ana Aparicio¹⁵, Andrew J Armstrong¹⁶, Diogo Assed Bastos¹⁷, Gerhardt Attard¹⁸, Karol Axcrona¹⁹, Mouna Ayadi²⁰, Himisha Beltran²¹, Anders Bjartell²², Pierre Blanchard²³, Maria T Bourlon²⁴, Alberto Briganti²⁵, Muhammad Bulbul²⁶, Consuelo Buttigliero²⁷, Orazio Caffo²⁸, Daniel Castellano²⁹, Elena Castro²⁹, Heather H Cheng³⁰, Kim N Chi³¹, Caroline S Clarke³², Noel Clarke³³, Johann S de Bono³⁴, Maria De Santis³⁵, Ignacio Duran³⁶, Eleni Efstathiou³⁷, Onyeanunam N Ekeke³⁸, Tamer I H El Nahas³⁹, Louise Emmett⁴⁰, Stefano Fanti⁴¹, Omolara A Fatiregun⁴², Felix Y Feng⁴³, Peter C C Fong⁴⁴, Valerie Fonteyne⁴⁵, Nicola Fossati⁴⁶, Daniel J George⁴⁷, Martin E Gleave⁴⁸, Gwenaelle Gravis⁴⁹, Susan Halabi⁵⁰, Daniel Heinrich⁵¹, Ken Herrmann⁵², Michael S Hofman⁵³, Thomas A Hope⁵⁴, Lisa G Horvath⁵⁵, Maha H A Hussain⁵⁶, Barbara Alicja Jereczek-Fossa⁵⁷, Robert J Jones⁵⁸, Anthony M Joshua⁵⁹, Ravindren Kanesvaran⁶⁰, Daniel Keizman⁶¹, Raja B Khauli⁶², Gero Kramer⁶³, Stacy Loeb⁶⁴, Brandon A Mahal⁶⁵, Fernando C Maluf⁶⁶, Joaquin Mateo⁶⁷, David Matheson⁶⁸, Mika P Matikainen⁶⁹, Ray McDermott⁷⁰, Rana R McKay⁷¹, Niven Mehra⁷², Axel S Merseburger⁷³, Alicia K Morgans⁷⁴, Michael J Morris⁷⁵, Hind Mrabti⁷⁶, Deborah Mukherji⁷⁷, Declan G Murphy⁷⁸, Vedang Murthy⁷⁹, Shingai B A Mutambirwa⁸⁰, Paul L Nguyen⁸¹, William K Oh⁸², Piet Ost⁸³, Joe M O'Sullivan⁸⁴, Anwar R Padhani⁸⁵, Chris Parker³⁴, Darren M C Poon⁸⁶, Colin C Pritchard⁸⁷, Danny M Rabah⁸⁸, Dana Rathkopf⁷⁵, Robert E Reiter⁸⁹, Raphaele Renard-Penna⁹⁰, Charles J Ryan¹⁴, Fred Saad⁹¹, Juan Pablo Sade⁹², Shahneen Sandhu⁵³, Oliver A Sartor⁹³, Edward Schaeffer⁵⁶, Howard I Scher⁷⁵, Nima Sharifi⁹⁴, Iwona A Skoneczna⁹⁵, Howard R Soule⁹⁶, Daniel E Spratt⁹⁷, Sandy Srinivas⁹⁸, Cora N Sternberg⁹⁹, Hiroyoshi Suzuki¹⁰⁰, Mary-Ellen Taplin¹⁰¹, Camilla Thellenberg-Karlsson¹⁰², Derya Tilki¹⁰³, Levent N Türkeri¹⁰⁴, Hiroji Uemura¹⁰⁵, Yüksel Ürün¹⁰⁶, Claire L Vale¹⁰⁷, Neha Vapiwala¹⁰⁸, Jochen Walz¹⁰⁹, Kosj Yamoah¹¹⁰, Dingwei Ye¹¹¹, Evan Y Yu³⁰, Almudena Zapatero¹¹², Aurelius Omlin¹¹³

Affiliations

¹ Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch.
² Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³ Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia.
⁴ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁶ Institute of Cancer Research, London, UK.
⁷ Carolina Urologic Research Center and GenesisCare, Myrtle Beach, SC, USA.
⁸ Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA.
⁹ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
¹⁰ South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
¹¹ Division of Urology, Clinique Universitaire St. Luc, Brussels, Belgium.
¹² Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland.
¹³ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
¹⁴ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹⁵ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Center for Prostate and Urologic Cancer, Duke Cancer Institute, Duke University, Durham, NC, USA.
¹⁷ Hospital Sirio-Libanês, São Paulo, Brazil.
¹⁸ UCL Cancer Institute, University College London, London, UK.
¹⁹ Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, Norway.
²⁰ Salah Azaiz Institute, Medical School of Tunis, Tunis, Tunisia.
²¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
²² Department of Urology, Skåne University Hospital, Malmö, Sweden.
²³ Department of Radiation Oncology, Oncostat U1018 INSERM, Université Paris-Saclay, Gustave-Roussy, Villejuif, France.
²⁴ Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
²⁵ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
²⁶ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
²⁷ Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Italy.
²⁸ Medical Oncology Department, Santa Chiara Hospital, APSS, Trento, Italy.
²⁹ Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
³⁰ Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA; Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA USA.
³¹ BC Cancer and University of British Columbia, Vancouver, Canada.
³² Research Department of Primary Care and Population Health, University College London, London, UK.
³³ The Christie and Salford Royal Hospitals, Manchester, UK.
³⁴ Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
³⁵ Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
³⁶ Medical Oncology Department, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
³⁷ Houston Methodist Cancer Center, Houston, TX, USA.
³⁸ Urology Division, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
³⁹ Kasr Al Ainy Hospital, Cairo University, Giza, Egypt.
⁴⁰ Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, UNSW Sydney, Sydney, Australia.
⁴¹ Department of Nuclear Medicine, IRCCS AOU Bologna, Bologna, Italy.
⁴² Lagos State University Teaching Hospital, Ikeja, Nigeria.
⁴³ University of California-San Francisco, San Francisco, CA, USA.
⁴⁴ Auckland City Hospital and University of Auckland, Auckland, New Zealand.
⁴⁵ Ghent University Hospital, Ghent, Belgium.
⁴⁶ Department of Surgery (Urology Service), Ente Ospedaliero Cantonale, Università della Svizzera Italiana Lugano, Switzerland.
⁴⁷ Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
⁴⁸ Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
⁴⁹ Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
⁵⁰ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
⁵¹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
⁵² Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany.
⁵³ Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁵⁴ Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA.
⁵⁵ Chris O'Brien Lifehouse, University of Sydney, Sydney, Australia.
⁵⁶ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
⁵⁷ Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy.
⁵⁸ School of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁵⁹ Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia.
⁶⁰ Division of Medical Oncology, National Cancer Centre, Singapore.
⁶¹ Genitourinary Unit, Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
⁶² Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon; Division of Urology, Carle-Illinois College of Medicine, Urbana, IL, USA.
⁶³ Department of Urology, Medical University of Vienna, Vienna, Austria.
⁶⁴ Department of Urology and Population Health, New York University Langone Health, New York, NY, USA; Department of Surgery/Urology, Manhattan Veterans Affairs, New York, NY, USA.
⁶⁵ Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA.
⁶⁶ Beneficiência Portuguesa de São Paulo, São Paulo, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brazil.
⁶⁷ Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
⁶⁸ Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK.
⁶⁹ Department of Urology, Helsinki University Hospital, Helsinki, Finland.
⁷⁰ Department of Medical Oncology, St. Vincent's University Hospital and Cancer Trials, Dublin, Ireland.
⁷¹ University of California-San Diego, Palo Alto, CA, USA.
⁷² Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands.
⁷³ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
⁷⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁵ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷⁶ Institut National d'Oncologie, Mohamed V University, Rabat, Morocco.
⁷⁷ Clemenceau Medical Center, Dubai, United Arab Emirates; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
⁷⁸ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷⁹ Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁸⁰ Department of Urology, Sefako Makgatho Health Science University, Dr. George Mukhari Academic Hospital, Medunsa, South Africa.
⁸¹ Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁸² Division of Hematology and Medical Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA.
⁸³ Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁸⁴ Patrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
⁸⁵ Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.
⁸⁶ Hong Kong Sanatorium and Hospital, Chinese University of Hong Kong, Hong Kong, China.
⁸⁷ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁸⁸ Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
⁸⁹ University of California-Los Angeles, Los Angeles, CA, USA.
⁹⁰ Department of Imagery, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France.
⁹¹ Centre Hospitalier de Université de Montréal, Montreal, Canada.
⁹² Instituto Alexander Fleming, Buenos Aires, Argentina.
⁹³ Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
⁹⁴ Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
⁹⁵ Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
⁹⁶ Prostate Cancer Foundation, Santa Monica, CA, USA.
⁹⁷ Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁹⁸ Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
⁹⁹ Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
¹⁰⁰ Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
¹⁰¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹⁰² Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
¹⁰³ Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
¹⁰⁴ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
¹⁰⁵ Yokohama City University Medical Center, Yokohama, Japan.
¹⁰⁶ Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
¹⁰⁷ MRC Clinical Trials Unit, University College London, London, UK.
¹⁰⁸ Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰⁹ Institut Paoli-Calmettes Cancer Center, Marseille, France.
¹¹⁰ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
¹¹¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
¹¹² University Hospital La Princesa, Health Research Institute, Madrid, Spain.
¹¹³ Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.

PMID: 39394013
DOI: 10.1016/j.eururo.2024.09.017

Free article

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Silke Gillessen et al. Eur Urol. 2025 Feb.

Free article

. 2025 Feb;87(2):157-216.

doi: 10.1016/j.eururo.2024.09.017. Epub 2024 Oct 11.

Authors

Affiliations

¹ Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland. Electronic address: silke.gillessen@eoc.ch.
² Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
³ Monash University, Melbourne, Australia; Eastern Health, Melbourne, Australia.
⁴ Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
⁵ Institut Gustave Roussy, University of Paris Saclay, Villejuif, France.
⁶ Institute of Cancer Research, London, UK.
⁷ Carolina Urologic Research Center and GenesisCare, Myrtle Beach, SC, USA.
⁸ Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA.
⁹ Massachusetts General Hospital Cancer Center, Boston, MA, USA.
¹⁰ South Australian Immunogenomics Cancer Institute, University of Adelaide, Adelaide, Australia.
¹¹ Division of Urology, Clinique Universitaire St. Luc, Brussels, Belgium.
¹² Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland; Faculty of Biosciences, Università della Svizzera Italiana, Lugano, Switzerland.
¹³ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
¹⁴ Masonic Cancer Center, University of Minnesota, Minneapolis, MN, USA.
¹⁵ Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
¹⁶ Center for Prostate and Urologic Cancer, Duke Cancer Institute, Duke University, Durham, NC, USA.
¹⁷ Hospital Sirio-Libanês, São Paulo, Brazil.
¹⁸ UCL Cancer Institute, University College London, London, UK.
¹⁹ Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway; Department of Urology, Akershus University Hospital, Lørenskog, Norway.
²⁰ Salah Azaiz Institute, Medical School of Tunis, Tunis, Tunisia.
²¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Harvard Medical School, Boston, MA, USA.
²² Department of Urology, Skåne University Hospital, Malmö, Sweden.
²³ Department of Radiation Oncology, Oncostat U1018 INSERM, Université Paris-Saclay, Gustave-Roussy, Villejuif, France.
²⁴ Instituto Nacional de Ciencias Medicas y Nutrición Salvador Zubirán, Mexico City, Mexico.
²⁵ Unit of Urology/Division of Oncology, Urological Research Institute, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
²⁶ Division of Urology, Department of Surgery, American University of Beirut Medical Center, Beirut, Lebanon.
²⁷ Department of Oncology, San Luigi Hospital, University of Turin, Orbassano, Italy.
²⁸ Medical Oncology Department, Santa Chiara Hospital, APSS, Trento, Italy.
²⁹ Department of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
³⁰ Department of Medicine, Division of Hematology and Oncology, University of Washington, Seattle, WA, USA; Division of Clinical Research, Fred Hutchinson Cancer Center, Seattle, WA USA.
³¹ BC Cancer and University of British Columbia, Vancouver, Canada.
³² Research Department of Primary Care and Population Health, University College London, London, UK.
³³ The Christie and Salford Royal Hospitals, Manchester, UK.
³⁴ Institute of Cancer Research, London, UK; Royal Marsden Hospital, London, UK.
³⁵ Department of Urology, Charité Universitätsmedizin Berlin, Berlin, Germany; Department of Urology, Medical University of Vienna, Vienna, Austria.
³⁶ Medical Oncology Department, Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain.
³⁷ Houston Methodist Cancer Center, Houston, TX, USA.
³⁸ Urology Division, University of Port Harcourt Teaching Hospital, Port Harcourt, Nigeria.
³⁹ Kasr Al Ainy Hospital, Cairo University, Giza, Egypt.
⁴⁰ Department of Theranostics and Nuclear Medicine, St. Vincent's Hospital, Sydney, Australia; Faculty of Medicine, UNSW Sydney, Sydney, Australia.
⁴¹ Department of Nuclear Medicine, IRCCS AOU Bologna, Bologna, Italy.
⁴² Lagos State University Teaching Hospital, Ikeja, Nigeria.
⁴³ University of California-San Francisco, San Francisco, CA, USA.
⁴⁴ Auckland City Hospital and University of Auckland, Auckland, New Zealand.
⁴⁵ Ghent University Hospital, Ghent, Belgium.
⁴⁶ Department of Surgery (Urology Service), Ente Ospedaliero Cantonale, Università della Svizzera Italiana Lugano, Switzerland.
⁴⁷ Departments of Medicine and Surgery, Duke Cancer Institute, Duke University, Durham, NC, USA.
⁴⁸ Department of Urologic Sciences, University of British Columbia, Vancouver, Canada.
⁴⁹ Department of Medical Oncology, Institut Paoli Calmettes, Aix-Marseille Université, Marseille, France.
⁵⁰ Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, USA.
⁵¹ Department of Oncology and Radiotherapy, Innlandet Hospital Trust, Gjøvik, Norway.
⁵² Department of Nuclear Medicine, University of Duisburg-Essen, Essen, Germany; German Cancer Consortium, University Hospital Essen, Essen, Germany.
⁵³ Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Peter MacCallum Cancer Centre, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia.
⁵⁴ Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA.
⁵⁵ Chris O'Brien Lifehouse, University of Sydney, Sydney, Australia.
⁵⁶ Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL, USA.
⁵⁷ Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy; Department of Radiation Oncology, European Institute of Oncology IRCCS, Milan, Italy.
⁵⁸ School of Cancer Sciences, University of Glasgow, Glasgow, UK.
⁵⁹ Department of Medical Oncology, Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, Australia.
⁶⁰ Division of Medical Oncology, National Cancer Centre, Singapore.
⁶¹ Genitourinary Unit, Division of Oncology, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel.
⁶² Naef K. Basile Cancer Institute, American University of Beirut Medical Center, Beirut, Lebanon; Division of Urology, Carle-Illinois College of Medicine, Urbana, IL, USA.
⁶³ Department of Urology, Medical University of Vienna, Vienna, Austria.
⁶⁴ Department of Urology and Population Health, New York University Langone Health, New York, NY, USA; Department of Surgery/Urology, Manhattan Veterans Affairs, New York, NY, USA.
⁶⁵ Department of Radiation Oncology, University of Miami Sylvester Cancer Center, Miami, FL, USA.
⁶⁶ Beneficiência Portuguesa de São Paulo, São Paulo, Brazil; Departamento de Oncologia, Hospital Israelita Albert Einstein, São Paulo, Brazil.
⁶⁷ Vall d'Hebron Institute of Oncology, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
⁶⁸ Faculty of Education Health and Wellbeing, University of Wolverhampton, Walsall, UK.
⁶⁹ Department of Urology, Helsinki University Hospital, Helsinki, Finland.
⁷⁰ Department of Medical Oncology, St. Vincent's University Hospital and Cancer Trials, Dublin, Ireland.
⁷¹ University of California-San Diego, Palo Alto, CA, USA.
⁷² Department of Medical Oncology, Radboudumc, Nijmegen, The Netherlands.
⁷³ Department of Urology, University Hospital Schleswig-Holstein, Lübeck, Germany.
⁷⁴ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA; Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
⁷⁵ Genitourinary Oncology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
⁷⁶ Institut National d'Oncologie, Mohamed V University, Rabat, Morocco.
⁷⁷ Clemenceau Medical Center, Dubai, United Arab Emirates; Division of Hematology and Oncology, Department of Internal Medicine, American University of Beirut, Beirut, Lebanon.
⁷⁸ Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia; Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.
⁷⁹ Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India.
⁸⁰ Department of Urology, Sefako Makgatho Health Science University, Dr. George Mukhari Academic Hospital, Medunsa, South Africa.
⁸¹ Department of Radiation Oncology, Brigham and Women's Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
⁸² Division of Hematology and Medical Oncology, Tisch Cancer Institute at Mount Sinai, New York, NY, USA.
⁸³ Department of Radiation Oncology, Iridium Network, Antwerp, Belgium; Department of Human Structure and Repair, Ghent University, Ghent, Belgium.
⁸⁴ Patrick G. Johnston Centre for Cancer Research, Queen's University, Belfast, UK.
⁸⁵ Paul Strickland Scanner Centre, Mount Vernon Cancer Centre, Northwood, UK.
⁸⁶ Hong Kong Sanatorium and Hospital, Chinese University of Hong Kong, Hong Kong, China.
⁸⁷ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA, USA.
⁸⁸ Cancer Research Chair and Department of Surgery, College of Medicine, King Saud University, Riyadh, Saudi Arabia; Department of Urology, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia.
⁸⁹ University of California-Los Angeles, Los Angeles, CA, USA.
⁹⁰ Department of Imagery, GRC 5 Predictive Onco-Uro, Pitie-Salpetriere Hospital, AP-HP, Sorbonne University, Paris, France.
⁹¹ Centre Hospitalier de Université de Montréal, Montreal, Canada.
⁹² Instituto Alexander Fleming, Buenos Aires, Argentina.
⁹³ Department of Medical Oncology, Mayo Clinic Comprehensive Cancer Center, Rochester, MN, USA.
⁹⁴ Desai Sethi Urology Institute and Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, FL, USA.
⁹⁵ Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.
⁹⁶ Prostate Cancer Foundation, Santa Monica, CA, USA.
⁹⁷ Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Cleveland, OH, USA.
⁹⁸ Division of Medical Oncology, Stanford University Medical Center, Stanford, CA, USA.
⁹⁹ Englander Institute for Precision Medicine, Weill Cornell Medicine, Division of Hematology and Oncology, Meyer Cancer Center, New York Presbyterian Hospital, New York, NY, USA.
¹⁰⁰ Department of Urology, Toho University Sakura Medical Center, Sakura, Japan.
¹⁰¹ Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
¹⁰² Department of Diagnostics and Intervention, Oncology, Umeå University, Umeå, Sweden.
¹⁰³ Martini-Klinik Prostate Cancer Center and Department of Urology, University Hospital Hamburg Eppendorf, Hamburg, Germany.
¹⁰⁴ Department of Urology, M.A. Aydınlar Acıbadem University, Altunizade Hospital, Istanbul, Turkey.
¹⁰⁵ Yokohama City University Medical Center, Yokohama, Japan.
¹⁰⁶ Department of Medical Oncology, Ankara University School of Medicine, Ankara, Turkey.
¹⁰⁷ MRC Clinical Trials Unit, University College London, London, UK.
¹⁰⁸ Department of Radiation Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA, USA.
¹⁰⁹ Institut Paoli-Calmettes Cancer Center, Marseille, France.
¹¹⁰ H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
¹¹¹ Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
¹¹² University Hospital La Princesa, Health Research Institute, Madrid, Spain.
¹¹³ Onkozentrum Zurich, University of Zurich and Tumorzentrum Hirslanden Zurich, Zurich, Switzerland.

PMID: 39394013
DOI: 10.1016/j.eururo.2024.09.017

Abstract

Background and objective: Innovations have improved outcomes in advanced prostate cancer (PC). Nonetheless, we continue to lack high-level evidence on a variety of topics that greatly impact daily practice. The 2024 Advanced Prostate Cancer Consensus Conference (APCCC) surveyed experts on key questions in clinical management in order to supplement evidence-based guidelines. Here we present voting results for questions from APCCC 2024.

Methods: Before the conference, a panel of 120 international PC experts used a modified Delphi process to develop 183 multiple-choice consensus questions on eight different topics. Before the conference, these questions were administered via a web-based survey to the voting panel members ("panellists").

Key findings and limitations: Consensus was a priori defined as ≥75% agreement, with strong consensus defined as ≥90% agreement. The voting results show varying degrees of consensus, as discussed in this article and detailed in the Supplementary material. These findings do not include a formal literature review or meta-analysis.

Conclusions and clinical implications: The voting results can help physicians and patients navigate controversial areas of clinical management for which high-level evidence is scant or conflicting. The findings can also help funders and policymakers in prioritising areas for future research. Diagnostic and treatment decisions should always be individualised on the basis of patient and cancer characteristics, and should incorporate current and emerging clinical evidence, guidelines, and logistic and economic factors. Enrolment in clinical trials is always strongly encouraged. Importantly, APCCC 2024 once again identified important gaps (areas of nonconsensus) that merit evaluation in specifically designed trials.

Keywords: Adjuvant therapy; Biochemical recurrence; Bone protection; Genetics and genomics; Hormonal treatment; Next-generation imaging; Positron emission tomography; Prostate cancer; Prostate-specific membrane antigen; Salvage therapy.

PubMed Disclaimer

Cited by

Darolutamide plus androgen-deprivation therapy: propensity score matching of ARASEC and historic clinical trial patients.
McKay RR, Ross AE, Preston MA, Gregg JR, Salami SS, Littleton N, Constantinovici N, Srinivasan S, Verholen F, Shore ND. McKay RR, et al. Future Oncol. 2025 May;21(11):1365-1375. doi: 10.1080/14796694.2025.2482360. Epub 2025 Apr 1. Future Oncol. 2025. PMID: 40165634 Free PMC article. Clinical Trial.
Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.
Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P. Zapatero A, et al. Oncol Rev. 2025 Jul 25;19:1599292. doi: 10.3389/or.2025.1599292. eCollection 2025. Oncol Rev. 2025. PMID: 40787089 Free PMC article. Review.
Stereotactic total ablative radiotherapy with MR-LINAC for synchronous oligometastatic prostate cancer.
Poon DM, Yuan J, Wong OL, Yang B, Chiu ST, Cheung KY, Chiu G, Yu SK. Poon DM, et al. Front Oncol. 2025 Jul 3;15:1607610. doi: 10.3389/fonc.2025.1607610. eCollection 2025. Front Oncol. 2025. PMID: 40678057 Free PMC article.
Utility of the prostest to predict and monitor response to chemotherapy in metastatic Castration-Resistant prostate cancer: A prospective pilot study.
Rahbar K, Schlack K, Bögemann M. Rahbar K, et al. BMC Cancer. 2025 Jul 10;25(1):1159. doi: 10.1186/s12885-025-14549-3. BMC Cancer. 2025. PMID: 40640763 Free PMC article.
Secondary Analysis of PSA and BCR-Free Survival in Asian Prostate Cancer Patients.
Gao X, Fu Y, Mo Z, Ruan Y. Gao X, et al. Cancer Manag Res. 2025 Jun 24;17:1205-1214. doi: 10.2147/CMAR.S527092. eCollection 2025. Cancer Manag Res. 2025. PMID: 40584226 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Affiliations

Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)

Authors

Affiliations

Abstract

Similar articles

Cited by

Publication types

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Abstract

Similar articles

Cited by

Publication types

MeSH terms

Related information

LinkOut - more resources

Full Text Sources

Medical